Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (OTCPK:AZNCF)

AstraZeneca Highlights Continued Progress of Oncology Pipeline at ASCO 2016 Leadership in DNA Damage Response Therapies

Business Wire May 19, 2016

Directorate Change

UK Regulatory news services, from the LSE May 18, 2016

TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL

UK Regulatory news services, from the LSE May 18, 2016

POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA

UK Regulatory news services, from the LSE May 17, 2016

Placing to Raise £665,000 gross

UK Regulatory news services, from the LSE May 17, 2016

Offer Update

UK Regulatory news services, from the LSE May 17, 2016

Oxford BioMedica Appoints Corporate Broker

UK Regulatory news services, from the LSE May 17, 2016

AstraZeneca Announces Positive Results from Benralizumab Phase III Program in Severe Asthma

Business Wire May 17, 2016

SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US

UK Regulatory news services, from the LSE May 12, 2016

Annual General Meeting

UK Regulatory news services, from the LSE May 12, 2016

Conclusion of Strategic Review and Trading Update

UK Regulatory news services, from the LSE May 12, 2016

Launch and pricing of EUR2.2bn bond issues

UK Regulatory news services, from the LSE May 9, 2016

Publication of a Prospectus

UK Regulatory news services, from the LSE May 5, 2016

AstraZeneca completes divestment of Imdur

UK Regulatory news services, from the LSE May 3, 2016

Hang Seng Bank 1st Interim Dividend for 2016

UK Regulatory news services, from the LSE May 3, 2016

HSBC Holdings 2016 Results Presentation

UK Regulatory news services, from the LSE May 3, 2016

HSBC Finance Corporation Form 8-K

UK Regulatory news services, from the LSE May 3, 2016

Avita Medical's Technology at Vitiligo Conferences

UK Regulatory news services, from the LSE May 3, 2016

AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY

UK Regulatory news services, from the LSE May 3, 2016

Loan Update

UK Regulatory news services, from the LSE May 3, 2016